Minireviews
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Rheumatol. Nov 12, 2013; 3(3): 32-39
Published online Nov 12, 2013. doi: 10.5499/wjr.v3.i3.32
Hot topics in lupus pregnancy
Javier A Cavallasca, Cecilia A Costa, Maria del Rosario Maliandi, Jorge L Musuruana
Javier A Cavallasca, Cecilia A Costa, Maria del Rosario Maliandi, Jorge L Musuruana, Sección Reumatología y Enfermedades Autoinmunes Sistémicas, Hospital JB Iturraspe, CP 3000, Santa Fe, Argentina
Author contributions: All the authors contributed equally to the analysis and interpretation of the data as well as to the preparation of the manuscript.
Correspondence to: Javier A Cavallasca, MD, Sección Reumatología y Enfermedades Autoinmunes Sistémicas, Hospital JB Iturraspe, Bv. Pellegrini 3551, CP 3000, Santa Fe, Argentina. jcavallasca@yahoo.com.ar
Telephone: +54-342-4555019 Fax: +54-342-4555019
Received: June 27, 2013
Revised: September 30, 2013
Accepted: November 1, 2013
Published online: November 12, 2013
Core Tip

Core tip: Systemic lupus erythematosus (SLE) typically affects women in their childbearing age. The effect of pregnancy on the disease and the effect of SLE on pregnancy and the fetus are highly important issues for the attending physician. The newborn may be affected by the onset of neonatal lupus erythematosus, either as a skin or blood disease, or by the presence of congenital heart block. The frequent association between SLE and antiphospholipid syndrome represents another risk situation. Optimization of pharmacological therapy before and during pregnancy should be done in order to reduce adverse events to the mother and the baby.